Genmab — Maj 2019
-
Solsen...Det får han pr. mail.
-
@Investorbro 15:41 on TV data, last week Jan said "So we expect the data since we now recruited all the over 100 patients now by the end of March. We expect the data basically early next year. So probably in the Q1 next year is where we anticipate the top line data."
-
I anledning af debuten fik Andrew fire spørgsmål på forhånd fra mig i morges som forsmag på, hvad der der ventede ham ved vores Q&A. Det gjorde jeg af hensyn til afviklingen, hvor vi skal have besvaret så mange spørgsmål som muligt på 45 minutter.
-
Det samme gør jeg med Zealand Pharmas nye CEO Emmanuel Dulac, når vi har Q&A med ham d. 29. maj.
-
God morgen
-
God morgen.
-
-
@NoHope, 2 sjæle en tanke
-
Poseida Therapeutics Reseives US FDA Orphan Drug designation for P-BCMA 101 for the treatment of MM https://m.firstwordpharma.com/poseida-therapeutics-receives-us-fda-orphan-drug-designation-p-bcma-101-treatment-multiple-myeloma
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind